Loading
Dxcover
Dxcover is a clinical-stage diagnostics company and University of Strathclyde spin-out. Its platform uses infrared spectroscopy of blood serum and AI algorithms to detect early-stage (Stage I/II) cancers, starting with brain and colorectal cancer, and it expanded to eight cancers in 2022. It is pre-commercial and works through clinical studies, CE/IVDR regulatory work and biopharma and diagnostic partnering. It raised a £7.5M Series A plus a £2.2M European Innovation Council grant (about £9.7M in total) in 2023, and a further ~£5M equity round in 2025 to support expansion into the US.
Funding
Every round, secondary, debt facility or acquisition involving Dxcover that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—